Omeros traded at $17.07 this Thursday November 5th, decreasing $1.11 or 6.11 percent since the previous trading session. Looking back, over the last four weeks, Omeros lost 7.78 percent. Over the last 12 months, its price rose by 159.42 percent. Looking ahead, we forecast Omeros to be priced at 18.05 by the end of this quarter and at 16.93 in one year, according to Trading Economics global macro models projections and analysts expectations.
Omeros Corporation is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system and immune-related diseases, including cancers. Its lead drug product OMIDRIA (phenylephrine and ketorolac intraocular solution) is used during cataract surgery or intraocular lens replacement for adult and pediatric patients. Its drug candidate narsoplimab is the subject of a biologics license application (BLA) for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). It also has multiple Phase III and Phase II clinical-stage development programs in its pipeline, which are focused on complement-mediated disorders, including immunoglobulin A (IgA) nephropathy, atypical hemolytic uremic syndrome (aHUS) and COVID-19.